Ubs Group Ag Anebulo Pharmaceuticals, Inc. Call Options Transaction History
Ubs Group Ag
- $452 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding ANEB
# of Institutions
14Shares Held
7.34MCall Options Held
0Put Options Held
0-
22 Nw, LP Seattle, WA5.37MShares$8.16 Million11.7% of portfolio
-
Lvw Advisors, LLC641KShares$974,3790.16% of portfolio
-
Nantahala Capital Management, LLC New Canaan, CT511KShares$776,8300.06% of portfolio
-
Morgan Stanley New York, NY399KShares$606,8120.0% of portfolio
-
Ikarian Capital, LLC Dallas, TX158KShares$239,9500.05% of portfolio
About Anebulo Pharmaceuticals, Inc.
- Ticker ANEB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 25,633,200
- Market Cap $39M
- Description
- Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing and commercializing treatments for people suffering from acute cannabinoid intoxication and substance addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist to treat cannabinoid intoxication and overdose. The ...